Background-The antiphospholipid syndrome (APS) entails a prothrombotic state associated with the presence of anticardiolipin antibodies (aCL). aCL were shown to promote endothelial cell and platelet activation and to induce an APS-like syndrome in mice when administered intravenously. Recent data suggest that aCL target the plasma cofactor ␤ 2 -glycoprotein I (␤2GPI) rather than negatively charged phospholipids. However, it has not been determined whether different epitope-specific anti-␤2GPI antibodies obtained from one patient possess pathogenic properties. Methods and Results-Three ␤2GPI-binding IgM monoclonal antibodies (mAbs) (ILA-1, ILA-3, and ILA-4) were cloned from a patient with APS. The three antibodies were shown to bind ␤2GPI immobilized on irradiated plates, yet only ILA-1 bound ␤2GPI coated onto nonirradiated plates. Furthermore, when using the anti-␤2GPI enzyme-linked immunosorbent assay, ILA-1 was the only mAb inhibited by fluid phase ␤2GPI. 
T he APS is characterized by a combination of clinical findings consisting of thromboembolic events, thrombocytopenia, and recurrent fetal loss in association with aCL. 1 The syndrome can accompany additional disorders defining it as secondary or exist as an isolated primary entity.
The clinical manifestations of APS have been considered to result from the occurrence of antibodies against negatively charged PLs. However, various hypotheses have been raised as to the true target of these antibodies. It has been suggested that aCL target either negatively charged PLs, various plasma cofactors, or, alternatively, an epitope exposed on either these molecules (ie, PLs or plasma cofactors) on their mutual interaction. [2] [3] [4] [5] One of the conceivable targets of aCL appears to be a 50-kD plasma cofactor termed ␤2GPI. 6 This glycoprotein, initially described by Schulze et al in 1961, 7 is composed of five respective consensus ("sushi") repeats.
8 ␤2GPI binds negatively charged PLs through a lysine-rich locus in the fifth domain 9, 10 and possesses several in vitro properties that define it as an anticoagulant (ie, inhibition of prothrombinase activity, ADPinduced platelet aggregation, or platelet factor IX production). 8 Several recent studies suggest that ␤2GPI alters its density 11 or exposes a cryptic epitope on its binding to PLs, which allows subsequent aCL binding. 12, 13 Emerging clinical studies 14, 15 reinforce these observations, thus confirming the specificity of "autoimmune" aCL to ␤2GPI to the point that some consider them to be anti-␤2GPI antibodies.
The role of aCL in conferring the prothrombotic predisposition in APS has been strengthened by in vitro studies showing their platelet- 16, 17 and EC- 18, 19 activating properties. Additionally, it has been demonstrated that passive transfer 20 or active immunization 21 with aCL of naive mice led to the clinical manifestations of APS. aCL have also been shown to possess thrombogenic properties in mice. 22, 23 However, it has not been established whether antibodies with different epitope specificities (ie, targeting different loci of the ␤2GPI) are capable of promoting activation of ECs and induction of an APS-equivalent mouse model. In the present study, we generated three IgM anti-␤2GPI mAbs from a patient with primary APS. We provide a description of their binding characteristics and show that despite their various epitope specificities, two mAbs had pathogenic properties manifested by in vitro activation of cultured ECs. Infusion of these mAbs to naive mice resulted in the clinical manifestations of APS.
Methods

Patient
The patient was a 32-year-old woman with primary APS, diagnosed after the occurrence of a previous episode of deep vein thrombosis and two abortions. The patient's serum was found to be positive for aCL (using the standard aCL ELISA) in high titers and for lupus anticoagulant.
Production of Human mAbs
Single-cell suspension of lymphocytes were derived from peripheral blood cells of a patient with primary APS. After a 5-day exposure to pokeweed mitogen (GIBCO Laboratory, Grand Island Biological Co), the lymphocytes were fused with the GM4672 human lymphoblastoid cell line according to a method described previously. 24 After fusion, the cells were seeded onto 96-well tissue culture plates (Nunc-Immunol), with hypoxanthine aminopterin thymidine selection media for 4 to 5 weeks. The clones were screened for binding to ␤2GPI with the modified aCL ELISA. All clones were subjected four times to limiting-dilution cloning procedures in a regular medium. The hybridomas were grown in culture supernatant. The culture fluid was collected, and ammonium precipitation (50%) was performed. Dialyzed ammonium precipitate was loaded onto anti-HIgM Sepharose columns (Pharmacia), and the immunoglobulins were eluted using 5 mol/L MgCl 2 and dialyzed against PBS.
The total IgM and IgG from the patient was prepared by combining the IgG and IgM prepared by loading 1 mL of the patient serum onto Sepharose anti-HIgG and anti-HIgM columns.
Detection of aCL
ELISA plates were coated with cardiolipin (Sigma Chemical) at a concentration of 50 g/mL in ethanol. Plates (Nunc) were blocked with 1% gelatin in PBS, and serial dilutions of the mAbs were added for 2 hours. Bound antibodies were detected using 1:10 000 dilution of goat anti-human IgM conjugated to alkaline phosphatase (Jackson ImmunoResearch) and the addition of its substrate p-nitrophenylphosphate. Absorbance was read at 405 nm in a Titertek ELISA reader (S.L.T. Laboratory Instruments).
Detection of mAb Reactivity by Modified aCL and Anti-␤2GPI ELISA
␤2GPI dependence of the binding of the mAbs to cardiolipin was assessed with a modified aCL ELISA. Cardiolipin coated onto ELISA plates were blocked with 1% gelatin in TBS and washed after 2 hours. Serial concentrations of ␤2GPI (0 to 100 g/mL) with 10 g/mL purified mAbs were added. The binding was detected as described above (aCL ELISA).
To detect reactivity of the mAbs with human mouse and bovine ␤2GPI, the CL-coated plates were blocked with different dilutions of human, mouse, or bovine sera (1% to 10% in TBS), followed by the addition of the mAbs (10 g/mL), and the assay was performed as described above.
For the purpose of determining the binding to human ␤2GPI alone, high binding (␥-irradiated; Nunc Maxisorp) or nonirradiated (Nunc Polysorp) plates were coated with purified human ␤2GPI (10 g/mL), the mAbs were added in different concentrations, and the ELISA was performed as described previously.
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Inhibition of Binding of Anti-␤2GPI mAbs by ␤2GPI
The concentration was determined of mAbs giving 50% maximal binding to ␤2GPI-coated plates. Different concentrations of ␤2GPI were preincubated with each of the mAbs for 2 hours and placed on precoated high-binding ␤2GPI-coated plates (Nunc) overnight at 4°C. The assay was continued as described in the anti-␤2GPI ELISA.
Detection of Anti-Endothelial Cell Antibodies
HUVECs were isolated as described previously and cultured under standard conditions. 25 Cells were used at passage 1 to 2 and plated onto gelatin-coated 96-well plates. Cyto-ELISA was performed as detailed previously.
26
Biotinylation of mAbs
The mAbs were dialyzed (100 g/100 L against 0.1 mol/L NaHCO 3 ) overnight at 4°C. NHS (biotinyamidocaproate n-hydroxy succinimide ester in 1 mL dimethylformamide; Sigma) biotin solution (2.5 L/100 L mAb) was added for 2 hours at room temperature and dialyzed against PBS.
Determination of ␤2GPI Epitopes Recognized by Different mAbs
To clarify whether the mAbs recognize similar epitopes on ␤2GPI, 50% of the binding of each of the mAbs onto ␤2GPI-coated plates was determined. Subsequently, each mAb and total immunoglobulins from the APS patient sera were biotinylated in a set of separate experiments. The purpose of the first experiment was to assess whether all the mAbs accounted for the total anti-␤2GPI reactivity of the APS patient sera. Thus, a mixture of the nonbiotinylated mAbs (ILA-1 plus ILA-2 plus ILA-4; final concentration, 100 g/mL) were used for competition with biotinylated total IgG. Subsequently, each of the nonbiotinylated mAbs (or control IgM) was used as competitors for binding in different concentrations (0 to 100 g/mL) to the single biotinylated mAb (at concentration giving 50% maximal binding) in the anti-␤2GPI ELISA. The binding was probed by streptavidin alkaline phosphatase (Jackson) and appropriate substrate. The percentage of inhibition was calculated as follows: % inhibitionϭabsorbance controlϪabsorbance with inhibitor/absorbance controlϫ100.
Adherence of U937 Cells to Endothelial Cells in the Presence of mAbs
The assay was performed as described previously. 27 Briefly, U937 (a monocyte/macrophage-like cell line) cells were pretreated with mouse anti-human anti-MHC class I mAb (PharMingen) for 30 minutes at 37°C (to block Fc receptor binding without affecting the activation of the ECs) and labeled with 0.5 Ci/mL [ 3 H]thymidine (Amersham International) for 24 hours. Adhesion assays were performed on HUVEC monolayers that were preincubated with ␤2GPI, and mAbs were added overnight. The EC monolayers were washed extensively, and radiolabeled U937 cells were added to each well, in RPMI 1640 medium containing 0.2% BSA for 30 minutes at 37°C. The nonadherent cells were removed by washing, and the cells were lysed with formic acid. Radioactivity associated with adherence was quantified by ␤-scintillation spectroscopy. The results were expressed as percentage of added U937 cells that adhered and are presented as meanϮSD from three to five replicate wells.
Selected Abbreviations and Acronyms
aCL ϭ anti-cardiolipin antibodies APS ϭ antiphospholipid syndrome aPTT ϭ activated partial thromboplastin time EC ϭ endothelial cell ELISA ϭ enzyme-linked immunosorbent assay ␤2GPI ϭ ␤ 2 -glycoprotein I HUVEC ϭ human umbilical vein endothelial cell ICAM-1 ϭ intracellular adhesion molecule 1 mAb ϭ monoclonal antibody PL ϭ phospholipid VCAM-1 ϭ vascular cell adhesion molecule 1
ELISA for Detecting Expression of Adhesion Molecule
HUVECs were grown onto 96-well plates, preincubated with mAbs (100 g/mL), washed and fixed with 0.1% glutaraldehyde, and treated with PBS containing 0.2% Triton X-100 to permeabilize the cell membrane. 28 Plates were blocked with 3% BSA and incubated with biotinylated mouse anti-human E-selectin, anti-human ICAM-1, or anti-human VCAM-1 (PharMingen) (1 g/mL) for 1 hour. Cells were then exposed to streptavidin alkaline phosphatase (1:5000 dilution) and the appropriate substrate.
A separate set of experiments was designed to test the specificity of the effect of the mAbs on the expression of adhesion molecules. Accordingly, a cocktail of anti-ICAM-1, VCAM-1, and E-selectin mAbs (PharMingen) (20 g/mL each) was added to the HUVECs after preincubation with each of the mAbs (25 g/mL), and the assay was continued as described in the adhesion assays.
Induction of Murine Experimental APS
Mice were infused intravenously with 100 g of each of the mAbs at day 0 (the day at which a vaginal plug was observed after mating) and day 7 of pregnancy. 20 The mice were bled and killed on day 15 of pregnancy. Fetal resorptions, aPTT, and platelet counts (markers of the APS-equivalent in mice) were determined as described previously.
20,21
Statistical Analysis
In the solid phase assays and competition and inhibition experiments, the Student's t test was used for comparison between the mAbs. The ANOVA test was used for comparison between the clinical parameters in the experimental groups.
Results
Binding of Human mAbs to ␤2GPI and Cardiolipin
Three mAbs were generated (ILA-1, ILA-3, and ILA-4), all of which were of the IgM isotype. The three mAbs bound ␤2GPI added to CL in a dose-dependent manner, yet no binding was evident to cardiolipin alone (Fig 1A) . Binding to CL in the presence of ␤2GPI (10 g/mL) was as follows: ILA-3 absorbance, 1.302Ϯ0.104; ILA-1 absorbance, 1.008Ϯ0.098; ILA-4 absorbance, 1.005Ϯ0.118; and HIgM absorbance,0.145Ϯ0.113. Binding of mAbs to sample blanks (the assay devoid of CL) was negligible (mean absorbance: ILA-1, 0.091; ILA-3, 0.084; and ILA-4, 0.095).
Higher binding of the mAbs to CL was evident in the presence of increasing concentrations of human, mouse, and bovine serum (Fig 1B, 1C, and 1D, respectively) .
Binding of all three mAbs to ␤2GPI-coated high-binding plates was observed in a dose-dependent manner compared with control human IgM (Fig 2A) . However, when the antibodies were assayed on nonirradiated plates, dose-dependent binding to ␤2GPI was noted only with ILA-1 (Fig 2B) . evident in three separate experiment using high-binding plates (Fig 3) . The K d value of ILA-1 was estimated as Ϫ2ϫ10 
Inhibitory Effect of Fluid Phase
Epitope Recognition by mAbs and Total Immunoglobulins for Binding to ␤2GPI/CL
The mixture of the three mAbs obtained from the APS patient partially inhibited the binding of biotinylated total immunoglobulins from the APS patient through the use of the anti-␤2GPI ELISA (Fig 4) .
To assess whether the obtained mAbs were directed against different epitopes on ␤2GPI, we biotinylated each mAb and performed competition assays with either of the three nonbiotinylated mAbs (ILA-1, ILA-3, and ILA-4). Binding of ILA-1 to ␤2GPI was inhibited only by ILA-1, whereas no competition was achieved with ILA-3 and ILA-4 (ILA-1: 89Ϯ7% compared with 5Ϯ1% for ILA-3 and 7Ϯ1% for ILA-4, at ILA-1 concentrations of 30 g/mL). Binding of biotinylated ILA-3 was inhibited only by nonbiotinylated ILA-3 and not by ILA-1 or ILA-4 (ILA-3: 79Ϯ6%, 8Ϯ2% for ILA-1 and 6Ϯ1%
for ILA-4, at biotinylated ILA-3 concentrations of 30 g/mL), and binding of biotinylated ILA-4 was inhibited only by nonbiotinylated ILA-4 in comparison to ILA-1 and ILA-3 (ILA-4: 90Ϯ11%, 9Ϯ4% for ILA-1 and 7Ϯ2% for ILA-3, at ILA-4 concentration of 30 g/mL), thus suggesting that the three mAbs target different non-cross-reactive epitopes on the ␤2GPI.
Anticoagulant Activity of mAbs
The anticoagulant activity of each of the anti-␤2GPI mAbs was measured by the aPTT as described previously 20, 21 and is shown in Fig 5. 
Binding of mAbs to HUVECs by Cyto-ELISA
All three mAbs bound HUVECs through the use of a cyto-ELISA (Fig 6) . No significant differences were noted between the mAbs with respect to the binding to HUVECs. No binding to HUVECs was evident when the ECs were incubated in a serum-free medium (devoid of ␤2GPI) (Fig 6) . Figure 2 . Binding of the mAbs onto ␤2GPI-coated plates. ␥-irradiated (A) and nonirradiated (B) ELISA plates were coated with human ␤2GPI (10 g/mL), and different concentrations of mAbs or control human IgM were added after blocking with BSA. Binding was assayed as described for the anti-␤2GPI ELISA. Each of the mAbs at a concentration giving 50% binding to ␤2GPI was preincubated with different concentrations of fluid phase human ␤2GPI (0 to 500 g/mL). Binding was probed as described for the anti-␤2GPI ELISA.
Figure 4.
Competition assays using the three mAbs and total immunoglobulins in the anti-␤2GPI ELISA. The total immunoglobulins (Ig) from the APS patient at a concentration giving 50% binding (5 g/mL) were biotinylated (as described in "Methods"), and competition was performed using either the total patient Ig (IgGϩIgM), a mixture of the mAbs, or an irrelevant control (IgGϩIgM) using the anti-␤2GPI ELISA.
Effect of mAbs on Adhesion of U937 Cells to HUVECs
The adhesion of monocytes to EC is considered a marker of EC activation. The percentage of adhesion expresses the portion of added U937 cells adhering the HUVECs (thus reflecting the percentage of EC coverage by the moncytic cells). The most significant adhesion of U937 cells to EC was accomplished by preincubation of the U937 cells with ILA-1 and then subjecting them to HUVECs. Adhesion to EC was dependent on the dose of the ILA-1 mAb achieving a maximal 79Ϯ6% (at ILA-1 concentration of 50 g/mL) adhesion compared with control HIgM (3Ϯ2%) (PϽ.001) (Fig 7A) . A similar, although less pronounced, dose-dependent effect on adhesion was evident by preincubation with ILA-3 (at a concentration of 50 g/mL) reaching a 43Ϯ4% adhesion compared with control HIgM (3Ϯ2%) (PϽ.003). ILA-4 was not potent in affecting U937 adhesion, giving a negligible 13Ϯ2% compared with the control IgM inducing 3Ϯ2% adhesion (PϽ.5). Prior incubation with antibodies to ICAM-1, VCAM-1, and E-selectin using the same assays significantly decreased the effect of the ILA-3 but only partially that of ILA-1 on U937 adherence to ECs (Fig 7B) .
Preincubation with heat-aggregated IgG to block Fc receptor interactions (expressed by U937 cells) ruled out the possibility that the effects on adhesion resulted from nonspecific Fc interactions of the mAbs with the ECs or leukocytes.
Effect of mAbs on Expression of Adhesion Molecules by HUVECs
The most pronounced effect on E-selectin expression by HUVECs was evident after their preincubation with ILA-3 (absorbance, 1.674Ϯ0.112) (Fig 8) . Preincubation of the mAb ILA-1 with HUVECs also resulted in significant E-selectin expression (absorbance, 1.232Ϯ0.212), whereas ILA-4 and human IgM did not produce marked effects on E-selectin expression (absorbance, 0.457Ϯ0.078 for ILA-4 and 0.112Ϯ0.058 for human IgM; Fig 8) . Expression of ICAM-1 was most impressive with ILA-3 (absorbance, 1.365Ϯ0.01) compared with ILA-1 (absorbance, 0.856Ϯ0.075), ILA-4 (absorbance, 0.507Ϯ0.075), and control IgM (absorbance, 0.111Ϯ0.068).
A similar pattern was noted with VCAM-1 expression, obtaining the most significant effect with ILA-3 (absorbance, 0.989Ϯ0.100) in comparison with ILA-1 (absorbance, 0.779Ϯ0.091), ILA-4 (0.377Ϯ0.068), and control IgM (0.092Ϯ0.012).
Induction of APS Manifestations in Naive Pregnant Mice by mAbs
Significant fetal loss was induced after passive intravenous administration of two of the three mAbs. The fetal resorption percentage was mostly pronounced with ILA-3 compared with ILA-1, ILA-4, and normal IgM (Table) . Significantly reduced platelet counts were noted in the mice passively infused with ILA-1 and ILA-3 compared with ILA-4 and control human IgM (Table) . ILA-1 and ILA-3 prolonged aPTT significantly compared with ILA-4 and human IgM.
Discussion
In the present study, we cloned three IgM mAbs that bound ␤2GPI attached to solid phase coated CL. The antibodies were obtained from a single primary APS patient with well-documented thrombotic episodes. The competition assays using the different mAbs show that a mixture of the IgM (containing all three mAbs) was responsible for only a fraction of anti-␤2GPI activity in the serum of the patient. Thus, not all ␤2GPI-reactive antibodies from the patient serum were recovered. The three mAbs were found to target different domains on human ␤2GPI, evident by the competition assays. All mAbs bound ␤2GPI immobilized on high binding plates, yet only ILA-1 bound ␤2GPI coated onto nonirradiated plates. ILA-1 also was the only mAb inhibited by fluid phase human ␤2GPI. Thus, it appears that ILA-1 is directed to an epitope present on the native structure of ␤2GPI, whereas ILA-3 and ILA-4 recognize targets that are exposed on ␤2GPI after conformational changes (exposed by its binding to ␥-irradiated plates).
Two of the three mAbs (ILA-1 and ILA-3) induced activation of HUVECs manifested by enhanced adhesion of U937 cells, which was associated with an elevated expression of adhesion molecules (ICAM-1, VCAM-1, and E-selectin). It should be mentioned in this respect that the activating effect on the EC was not directly correlated with the binding to HUVECs as measured by the ELISA, thus excluding the Figure 5 . Anticoagulant activity of anti-␤2GPI mAbs. aPTT was measured (in seconds) when mAbs (5 g/mL) were added to a normal plasma using a mixing test with an equivalent dose of cephalin and incubation for 2 minutes at 37°C. Each point represent the meanϮSD of three separate experiments. Figure 6 . Binding of the mAbs to HUVECs. Cyto-ELISA using HUVECs was performed as described in "Methods." The binding to HUVECs was assessed in the absence and presence of ␤2GPI (10 g/mL).
possibility that mere binding of the mAbs to ECs is sufficient to elicit monocyte adhesion.
Several studies investigated the EC binding and activating properties of aCL. 18, 19, 29 In a very recent work, Simantov et al 19 used purified IgG aCL from patients with APS and demonstrated that these antibodies activated cultured HUVECs, as reflected by enhanced monocyte adherence to ECs and expression of adhesion molecules. The activation properties were found to depend on the presence of ␤2GPI in the medium. However, it was not possible to conclude whether the EC-activating effect is contributed by a single monospecific population of antibodies or, alternatively, induced by different subgroups of aCL. More recently, Del-Papa et al 18 showed that anti-␤2GPI antibodies from APS patients activated ECs provided ␤2GPI was present in the medium (assayed by the expression of adhesion molecules, IL-6, and 6-keto-prostaglandin 1␣ ). However, the correlation of these interesting in vitro findings with the procoagulant state induced in animal models of APS has not been investigated. In this study, we used three mAbs produced from the same patient that had different binding targets on ␤2GPI. Despite the differences in epitope binding, mAbs ILA-1 and ILA-3 were potent in promoting EC activation when added to a culture containing ␤2GPI. The EC-activating properties of aCL were previously presumed to result from attachment of the antibodies to ␤2GPI deposited on the EC surface after its preactivation and resultant exposure of negatively charged phosphatidylserine. This mechanism, however, remains largely speculative in view of the scarce evidence on loss of membrane asymmetry in EC. Regardless of the mechanism, our observations also show that all mAbs bound cardiolipin in the presence of mouse and bovine sera (presumably native ␤2GPI), a finding that could support the role of endogenous ␤2GPI-mediated activation of the EC in vivo.
Previously, we have shown that passive administration of monoclonal aCL as well as active immunization of naive BALB/c with these antibodies was capable of inducing experimental APS. 20, 21 The aCL-infused mice were found to develop thrombocytopenia, prolonged aPTT, and increased fetal resorptions after mating. These clinical parameters aided in establishing the primary pathogenicity of the antibodies. Moreover, antibodies produced by immunization with human ␤2GPI were found to induce APS in naive BALB/c mice, 30 thus supporting an important role of aCL in the pathogenesis of the syndrome.
Clinical Parameters in Pregnant Mice
In the present study, we used these parameters to assess the pathogenic potential of the three mAbs to sort out whether it could be attributed to a monospecific antibody. Herein, we show that two of the three mAbs produced from the same patient harbored pathogenic in vivo characteristics evidenced by the induction of a syndrome resembling human APS. The correlation between the pathogenic effects in the passive transfer experiments and the in vitro adherence assays was not complete. These findings could be explained by the multiple effects of aCL on hemostasis, including activation of platelets, 16 induction of tissue factor, 31 and so on. Furthermore, the effect of the mAbs on the EC seems to be multifactorial and probably is not restricted merely to expression of the three adhesion molecules that were evaluated. This observation is supported by the partial inhibitory effect of prior incubation with antibodies to adhesion molecules on the ILA-1-mediated EC-activation compared with the nearcomplete inhibition of the ILA-3 effect.
The results of the present study show for the first time that different anti-␤2GPI antibodies possess both EC-activating properties and are capable of inducing a murine APS.
